Pay in 4 interest-free payments of $5.83 Learn more
Ships within 48 hours · Estimated delivery Aug 4 - Aug 9
Korner J, Bessler M, Inabnet W, Taveras C, Holst JJ
Medications based on personal need as determined by third-party clinician
Triple agonists take this strategy further by targeting GLP-1R, GIPR, and the glucagon receptor (GCGR), aiming to regulate multiple complementary metabolic pathways
On average, patients regain about 60% of the weight they lost within a few months to a year after stopping the medication, even when maintaining healthy habits like proper nutrition and exercise
Numerous practice guidelines recommend multicomponent, evidence-based nutritional and behavioral therapy for adults with obesity, but use of such therapies with GLP-1s is not widespread
Additive mechanisms: central activation of GLP-1R / GIPR hypothalamic satiety circuits, slowed gastric emptying, amplified glucose-dependent insulin secretion, direct adipocyte lipolysis via GCGR, brown thermogenesis via UCP1, and increased hepatic lipid oxidation
US$ 22.02
US$ 20.01
US$ 26.48
US$ 26.54
